Trials / Completed
CompletedNCT01304511
Post-Marketing Surveillance of the Safety and Efficacy of Orgalutran (Ganirelix)®
Post-Marketing Surveillance Orgalutran (Ganirelix)®
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 711 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- Female
- Age
- —
- Healthy volunteers
- —
Summary
The purpose of this post-marketing surveillance is to identify problems and questions regarding the safety and efficacy of Orgalutran (Ganirelix)® when used for the prevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproduction techniques (ART).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Orgalutran |
Timeline
- Start date
- 2005-02-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2011-02-25
- Last updated
- 2024-04-03
Source: ClinicalTrials.gov record NCT01304511. Inclusion in this directory is not an endorsement.